Advanced search
Publication Cover
Dialogues in Clinical Neuroscience Volume 11, 2009 - Issue 4
Submit an article Journal homepage
1,978
Views
47
CrossRef citations to date
0
Altmetric
Pharmacological Aspects

Pharmacogenetics of antipsychotic-induced side effects

Farmacogenética de los efectos secundarios inducidos por los antipsicóticos

Pharmacogénétique des effets secondaires induits par les antipsychotiques

Todd LenczCenter for Translational Psychiatry, Feinstein Institute for Medical Research, North Shore - Long Island Jewish Health System, Glen Oaks, NY, USA; Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore - Long Island Jewish Health System, Glen Oaks, NY, USA; Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine, Bronx, NY, USACorrespondence[email protected]
&
Anil K. MalhotraCenter for Translational Psychiatry, Feinstein Institute for Medical Research, North Shore - Long Island Jewish Health System, Glen Oaks, NY, USA; Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore - Long Island Jewish Health System, Glen Oaks, NY, USA; Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine, Bronx, NY, USA
Pages 405-415 | Published online: 01 Apr 2022

Citations (47)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Daniel S. Helman. (2018) Recovery from Schizophrenia: An Autoethnography. Deviant Behavior 39:3, pages 380-399.
Read now
Xiaojie Ma, Tuerxun Maimaitirexiati, Rong Zhang, Xueping Gui, Wenhui Zhang, Guozheng Xu & Gang Hu. (2014) HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis. International Journal of Psychiatry in Clinical Practice 18:4, pages 229-242.
Read now
Nabilah I. Chowdhury, Renan P. Souza, Arun K. Tiwari, Eva J. Brandl, Michelle Sicard, Herbert Y. Meltzer, Jeffrey A. Lieberman, James L. Kennedy & Daniel J. Müller. (2014) Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. The World Journal of Biological Psychiatry 15:3, pages 251-258.
Read now
Lawrence Maayan & Christoph U Correll. (2010) Management of antipsychotic-related weight gain. Expert Review of Neurotherapeutics 10:7, pages 1175-1200.
Read now

Articles from other publishers (43)

Felice Iasevoli, Camilla Avagliano, Luigi D’Ambrosio, Annarita Barone, Mariateresa Ciccarelli, Giuseppe De Simone, Benedetta Mazza, Licia Vellucci & Andrea de Bartolomeis. (2023) Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal. Biomedicines 11:3, pages 895.
Crossref
Regina F. Nasyrova, Elena E. Vaiman, Vera V. Repkina, Aiperi K. Khasanova, Azat R. Asadullin, German A. Shipulin, Kuanysh S. Altynbekov, Mustafa Al-Zamil, Marina M. Petrova & Natalia A. Shnayder. (2023) Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review. Genes 14:3, pages 616.
Crossref
Diana Z. Paderina, Anastasiia S. Boiko, Ivan V. Pozhidaev, Irina A. Mednova, Anastasia A. Goncharova, Anna V. Bocharova, Olga Yu. Fedorenko, Elena G. Kornetova, Arkadiy V. Semke, Nikolay A. Bokhan, Anton J. M. Loonen & Svetlana A. Ivanova. (2022) The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia. Genes 13:8, pages 1312.
Crossref
D. V. Ivaschenko, L. V. Fedina, N. I. Buromskaya, P. V. Shimanov, R. V. Deitsch, M. I. Nastovich, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Y. S. Shevchenko & D. A. Sychev. (2021) Analysis of associations between pharmacodynamic genetic factors and antipsychotics’ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice:2, pages 78-88.
Crossref
Yi Su, Hao Yan, Liangkun Guo, Tianlan Lu, Dai Zhang & Weihua Yue. (2021) Association of MTHFR C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index. Frontiers in Psychiatry 12.
Crossref
Sarah E. Williford, Catherine J. Libby, Adetokunbo Ayokanmbi, Arphaxad Otamias, Juan J. Gordillo, Emily R. Gordon, Sara J. Cooper, Matthew Redmann, Yanjie Li, Corinne Griguer, Jianhua Zhang, Marek Napierala, Subramaniam Ananthan & Anita B. Hjelmeland. (2021) Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. PLOS ONE 16:5, pages e0250649.
Crossref
Sanne M. Kloosterboer, Karin M. Egberts, Brenda C. M. de Winter, Teun van Gelder, Manfred Gerlach, Manon H. J. Hillegers, Gwen C. Dieleman, Soma Bahmany, Catrien G. Reichart, Emma van Daalen, Mirjam E. J. Kouijzer, Bram Dierckx & Birgit C. P. Koch. (2020) Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents. Clinical Pharmacokinetics 59:11, pages 1393-1405.
Crossref
Nadine C. van der Burg, Asmar F. Y. Al Hadithy, Peter N. van Harten, Jim van Os & P. Roberto Bakker. (2020) The genetics of drug-related movement disorders, an umbrella review of meta-analyses. Molecular Psychiatry 25:10, pages 2237-2250.
Crossref
Svetlana Ivanova, Diana Paderina, Anastasiia Boiko, Olga Fedorenko, Ivan Pozhidaev, Vladimir Tigunsev, Elena Kornetova, Nikolay Bokhan, Bob Wilffert & Anton Loonen. (2020) COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients. COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients.
Daniel S. Helman. (2020) Nonmedical Interventions for Schizophrenia. Holistic Nursing Practice 34:2, pages 73-82.
Crossref
Anton JM Loonen, Bob Wilffert & Svetlana A Ivanova. (2019) Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. Pharmacogenomics 20:17, pages 1199-1223.
Crossref
Michael B. Centorino & Susan K. Schultz. 2019. Schizophrenia and Psychoses in Later Life. Schizophrenia and Psychoses in Later Life 55 68 .
Tinchou Li, Mingcheng Lee, Fuming Tsai, Yunhsiang Chen, Yiyin Lin & Maoliang Chen. (2018) Proteomic study revealed antipsychotics-induced nuclear protein regulations in B35 cells are similar to the regulations in C6 cells and rat cortex. BMC Pharmacology and Toxicology 19:1.
Crossref
Madison L. Gates, Thad Wilkins, Elizabeth Ferguson, Veronica Walker, Robert K. Bradford & Wonsuk Yoo. (2016) Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications. Health & Justice 4:1.
Crossref
S Mas, P Gassó, D Boloc, N Rodriguez, F Mármol, J Sánchez, M Bernardo & A Lafuente. (2015) Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. The Pharmacogenomics Journal 16:3, pages 293-300.
Crossref
Svetlana A Ivanova, Anton JM Loonen, P Roberto Bakker, Maxim B Freidin, Nienke J ter Woerds, Asmar FY Al Hadithy, Arkadiy V Semke, Olga Yu Fedorenko, Jacobus RBJ Brouwers, Nikolay A Bokhan, Jim van Os, Peter N van Harten & Bob Wilffert. (2016) Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Medicine 4, pages 205031211664367.
Crossref
Alessandro Serretti & Chiara Fabbri. 2016. Pharmacovigilance in Psychiatry. Pharmacovigilance in Psychiatry 121 146 .
Amilton dos Santos JúniorTaciane Barbosa HenriquesMaricilda Palandi de MelloAdriana Perez Ferreira NetoLúcia Arisaka PaesOsmar Henrique Della TorreLetícia Esposito SewaybrickerThiago Salum FontanaEloisa Helena Rubello Valler CeleriGil Guerra JúniorPaulo Dalgalarrondo. (2015) Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. Journal of Child and Adolescent Psychopharmacology 25:10, pages 738-748.
Crossref
Jian-Ping Zhang, Delbert G. Robinson, Juan A. Gallego, Majnu John, Jin Yu, Jean Addington, Mauricio Tohen, John M. Kane, Anil K. Malhotra & Todd Lencz. (2015) Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis . Schizophrenia Bulletin 41:6, pages 1248-1255.
Crossref
Paul P. Lerner, Chanoch Miodownik & Vladimir Lerner. (2015) Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. Psychiatry and Clinical Neurosciences 69:6, pages 321-334.
Crossref
Su Ling Young, Mark Taylor & Stephen M Lawrie. (2014) “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects . Journal of Psychopharmacology 29:4, pages 353-362.
Crossref
Christina A Castellani, Melkaye G Melka, Eric J Diehl, Benjamin I Laufer, Richard L O'Reilly & Shiva M Singh. (2015) DNA methylation in psychosis: insights into etiology and treatment. Epigenomics 7:1, pages 67-74.
Crossref
Melkaye G Melka, Benjamin I Laufer, Patrick McDonald, Christina A Castellani, Nagalingam Rajakumar, Richard O’Reilly & Shiva M Singh. (2014) The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clinical Epigenetics 6:1.
Crossref
Laura Pina-Camacho, Covadonga M. Díaz-Caneja, Pilar A. Saiz, Julio Bobes, Iluminada Corripio, Eva Grasa, Roberto Rodriguez-Jimenez, Miryam Fernández, Julio Sanjuán, Aurelio García-López, Cecilia Tapia-Casellas, María Álvarez-Blázquez, David Fraguas, Marina Mitjans, Bárbara Arias & Celso Arango. (2014) Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. Revista de Psiquiatría y Salud Mental (English Edition) 7:4, pages 166-178.
Crossref
Laura Pina-Camacho, Covadonga M. Díaz-Caneja, Pilar A. Saiz, Julio Bobes, Iluminada Corripio, Eva Grasa, Roberto Rodriguez-Jimenez, Miryam Fernández, Julio Sanjuán, Aurelio García-López, Cecilia Tapia-Casellas, María Álvarez-Blázquez, David Fraguas, Marina Mitjans, Bárbara Arias & Celso Arango. (2014) Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. Revista de Psiquiatría y Salud Mental 7:4, pages 166-178.
Crossref
A.C.C. Kao, M. Rojnic Kuzman, A.K. Tiwari, M.V. Zivkovic, N.I. Chowdhury, V. Medved, I. Kekin, C.C. Zai, J.A. Lieberman, H.Y. Meltzer, T. Bozina, N. Bozina, J.L. Kennedy, J. Sertic & D.J. Müller. (2014) Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of Psychiatric Research 54, pages 36-42.
Crossref
Pawel ZajdelAnna Partyka, Krzysztof Marciniec, Andrzej J Bojarski, Maciej Pawlowski & Anna Wesolowska. (2014) Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?. Future Medicinal Chemistry 6:1, pages 57-75.
Crossref
Bill W. Massey, Jiang Li & Herbert Y. Meltzer. 2014. Schizophrenia. Schizophrenia 161 173 .
Britt I. Drögemöller, Galen E.B. Wright, Dana J.H. Niehaus, Robin Emsley & Louise Warnich. (2013) Next-generation sequencing of pharmacogenes. Pharmacogenetics and Genomics 23:12, pages 666-674.
Crossref
Gerda de Kuijper, Hans Mulder, Heleen Evenhuis, Frans Scholte, Frank Visser & Pieter J. Hoekstra. (2013) Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Research in Developmental Disabilities 34:9, pages 2799-2809.
Crossref
Gerda de Kuijper, Hans Mulder, Heleen Evenhuis, Frank Visser & Pieter J. Hoekstra. (2013) Effects of Controlled Discontinuation of Long-Term Used Antipsychotics on Weight and Metabolic Parameters in Individuals With Intellectual Disability. Journal of Clinical Psychopharmacology 33:4, pages 520-524.
Crossref
Sergi Mas, Adrián LLerena, Jerónimo Saíz, Miquel Bernardo & Amalia Lafuente. (2012) Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13:15, pages 1773-1782.
Crossref
Robert Dent, Angelique Blackmore, Joan Peterson, Rami Habib, Gary Peter Kay, Alan Gervais, Valerie Taylor & George Wells. (2012) Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature. PLoS ONE 7:6, pages e36889.
Crossref
T A P Lett, T J M Wallace, N I Chowdhury, A K Tiwari, J L Kennedy & D J Müller. (2011) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular Psychiatry 17:3, pages 242-266.
Crossref
Joseph T. Coyle & Glenn T. Konopaske. 2012. Basic Neurochemistry. Basic Neurochemistry 1000 1011 .
James L. Roerig, Kristine J. Steffen & James E. Mitchell. (2011) Atypical Antipsychotic-Induced Weight Gain. CNS Drugs 25:12, pages 1035-1059.
Crossref
Antonio Drago, Concetta Crisafulli & Alessandro Serretti. (2011) The genetics of antipsychotic induced tremors: A genome‐wide pathway analysis on the STEP‐BD SCP sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156:8, pages 975-986.
Crossref
Vladimir Lerner & Chanoch Miodownik. (2011) Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment. Current Psychiatry Reports 13:4, pages 295-304.
Crossref
Leslie Citrome, Richard I.G. Holt, Daniel J. Walker & Vicki Poole Hoffmann. (2011) Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. Clinical Drug Investigation 31:7, pages 455-482.
Crossref
Nam Young Lee, Se Hyun Kim, Dong Chung Jung, Eun Young Kim, Han Young Yu, Ki Hye Sung, Ung Gu Kang, Yong Min Ahn & Yong Sik Kim. (2011) The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:5, pages 1273-1278.
Crossref
Nabilah I. Chowdhury, Gary Remington & James L. Kennedy. (2011) Genetics of Antipsychotic-induced Side Effects and Agranulocytosis. Current Psychiatry Reports 13:2, pages 156-165.
Crossref
Christoph U. Correll, Todd Lencz & Anil K. Malhotra. (2011) Antipsychotic drugs and obesity. Trends in Molecular Medicine 17:2, pages 97-107.
Crossref
Todd Lencz, Delbert G. Robinson, Barbara Napolitano, Serge Sevy, John M. Kane, David Goldman & Anil K. Malhotra. (2010) DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and Genomics 20:9, pages 569-572.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.